摘要
随着急性心肌梗死发病率的逐年上升,新的溶栓药物正在不断的研制中。重组人尿激酶原又称为单链尿激酶型纤溶酶原激活剂,它主要激活纤维蛋白表面的纤溶酶原,所以具有选择性溶栓作用,与其他溶栓药物相比,重组人尿激酶原具有疗效显著,不良反应小等优点。本文主要介绍重组人尿激酶原的结构、作用机制、药动学、临床疗效及不良反应。
With the increase in the morbidity of acute myocardial infarction, new thrombolytics are continually developed. Recombinant human prourokinase, also called single-chain urokinase-type plasminogen activator, is one of the new thrombolytics. It preferentially activates plasminogen on the fibrin surface, and induces fibrin-seletive clot lysis. It has the advantages of more potent efficacy and less adverse reactions in comparison with other thrombolytics. This article introduced the structure, action mechanism, pharmacokinetics, clinical efficacy and adverse reactions of recombinant human prourokinase.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2008年第5期430-432,共3页
Chinese Journal of New Drugs
关键词
重组人尿激酶原
尿激酶型纤溶酶原激活物
溶栓治疗
recombinant human prourokinase
urokinase-type plasminogen activator
thrombolytic therapy
